Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 434

1.

Effect of a pharmacist-managed hypertension program on health system costs: an evaluation of the Study of Cardiovascular Risk Intervention by Pharmacists-Hypertension (SCRIP-HTN).

Houle SK, Chuck AW, McAlister FA, Tsuyuki RT.

Pharmacotherapy. 2012 Jun;32(6):527-37. doi: 10.1002/j.1875-9114.2012.01097.x. Epub 2012 May 2.

PMID:
22552863
[PubMed - indexed for MEDLINE]
2.

The Asheville Project: clinical and economic outcomes of a community-based long-term medication therapy management program for hypertension and dyslipidemia.

Bunting BA, Smith BH, Sutherland SE.

J Am Pharm Assoc (2003). 2008 Jan-Feb;48(1):23-31. doi: 10.1331/JAPhA.2008.07140.

PMID:
18192127
[PubMed - indexed for MEDLINE]
3.

A randomized trial of the effect of community pharmacist and nurse care on improving blood pressure management in patients with diabetes mellitus: study of cardiovascular risk intervention by pharmacists-hypertension (SCRIP-HTN).

McLean DL, McAlister FA, Johnson JA, King KM, Makowsky MJ, Jones CA, Tsuyuki RT; SCRIP-HTN Investigators.

Arch Intern Med. 2008 Nov 24;168(21):2355-61. doi: 10.1001/archinte.168.21.2355.

PMID:
19029501
[PubMed - indexed for MEDLINE]
4.

Economic impact of community pharmacist intervention in cholesterol risk management: an evaluation of the study of cardiovascular risk intervention by pharmacists.

Simpson SH, Johnson JA, Tsuyuki RT.

Pharmacotherapy. 2001 May;21(5):627-35.

PMID:
11349751
[PubMed - indexed for MEDLINE]
5.

Diabetes Ten City Challenge: final economic and clinical results.

Fera T, Bluml BM, Ellis WM.

J Am Pharm Assoc (2003). 2009 May-Jun;49(3):383-91. doi: 10.1331/JAPhA.2009.09015.

PMID:
19357068
[PubMed - indexed for MEDLINE]
6.
7.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
[PubMed - indexed for MEDLINE]
8.

The Diabetes Ten City Challenge: interim clinical and humanistic outcomes of a multisite community pharmacy diabetes care program.

Fera T, Bluml BM, Ellis WM, Schaller CW, Garrett DG.

J Am Pharm Assoc (2003). 2008 Mar-Apr;48(2):181-90. doi: 10.1331/JAPhA.2008.07166.

PMID:
18359731
[PubMed - indexed for MEDLINE]
9.

Incremental costs associated with physician and pharmacist collaboration to improve blood pressure control.

Kulchaitanaroaj P, Brooks JM, Ardery G, Newman D, Carter BL.

Pharmacotherapy. 2012 Aug;32(8):772-80. doi: 10.1002/j.1875-9114.2012.01103.x.

PMID:
23307525
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients.

Milne RJ, Vander Hoorn S, Jackson RT.

Pharmacoeconomics. 1997 Sep;12(3):384-408.

PMID:
10170463
[PubMed - indexed for MEDLINE]
12.

Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.

Whitfield MD, Gillett M, Holmes M, Ogden E.

Public Health. 2006 Dec;120(12):1140-8. Epub 2006 Nov 3.

PMID:
17084425
[PubMed - indexed for MEDLINE]
13.

Assessment of the clinical and economic outcomes of pharmacy interventions in drug-related problems.

Westerlund T, Marklund B.

J Clin Pharm Ther. 2009 Jun;34(3):319-27. doi: 10.1111/j.1365-2710.2008.01017.x.

PMID:
19646078
[PubMed - indexed for MEDLINE]
14.

Physician-pharmacist comanagement of hypertension: a randomized, comparative trial.

Borenstein JE, Graber G, Saltiel E, Wallace J, Ryu S, Archi J, Deutsch S, Weingarten SR.

Pharmacotherapy. 2003 Feb;23(2):209-16.

PMID:
12587810
[PubMed - indexed for MEDLINE]
15.

Economic evaluation of pharmacist involvement in disease management in a community pharmacy setting.

Munroe WP, Kunz K, Dalmady-Israel C, Potter L, Schonfeld WH.

Clin Ther. 1997 Jan-Feb;19(1):113-23.

PMID:
9083713
[PubMed - indexed for MEDLINE]
16.

Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis.

Huse DM, Song X, Ozminkowski RJ, Maguire J, Williams SA, Borok GM, McDonough K.

Clin Ther. 2006 Sep;28(9):1425-42.

PMID:
17062315
[PubMed - indexed for MEDLINE]
17.

Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial.

Jönsson B, Carides GW, Burke TA, Dasbach EJ, Lindholm LH, Dahlöf B; LIFE Study Group.

J Hypertens. 2005 Jul;23(7):1425-31.

PMID:
15942467
[PubMed - indexed for MEDLINE]
18.

Patient self-management program for diabetes: first-year clinical, humanistic, and economic outcomes.

Garrett DG, Bluml BM.

J Am Pharm Assoc (2003). 2005 Mar-Apr;45(2):130-7.

PMID:
15868754
[PubMed - indexed for MEDLINE]
19.

Medication therapy management: 10 years of experience in a large integrated health care system.

Ramalho de Oliveira D, Brummel AR, Miller DB.

J Manag Care Pharm. 2010 Apr;16(3):185-95.

PMID:
20331323
[PubMed - indexed for MEDLINE]
Free Article
20.

Financial and health costs of uncontrolled blood pressure in the United Kingdom.

Lloyd A, Schmieder C, Marchant N.

Pharmacoeconomics. 2003;21 Suppl 1:33-41.

PMID:
12648033
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk